Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA).

Maxime DougadosJulien LucasEmilie DesfleursPascal ClaudepierrePhilippe GoupilleAdeline Ruyssen-WitrandAlain SarauxAnne TournadreDaniel WendlingCédric Lukas

Published in: RMD open (2023)

Following its approval in France, ~59% of axSpA patients retained secukinumab in daily practice, at 1 year. Prior exposure to TNFi, OSI and IBD were identified as risk factors for secukinumab discontinuation.

Keyphrases

ankylosing spondylitis
end stage renal disease
primary care
healthcare
ejection fraction
newly diagnosed
chronic kidney disease
rheumatoid arthritis
disease activity
peritoneal dialysis
prognostic factors
physical activity